drugset / Trial / NCT00496873
Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan
Phase 2
Completed
100 enrolled
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc. · collabPharmatech · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of the clinical research study is to learn if treatment with a combination of three drugs, Cytoxan (cyclophosphamide), Rituxan (rituximab) and Nipent (pentostatin), will help to control the disease in patients with previously untreated non-Hodgkin's lymphoma, CLL, or bulky lymphoma. The safety of this treatment will also be studied.
Timeline
- Start
- 2005-06
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 600 mg/m2 | Intravenous |
| Subject | Pentostatin | Small molecule | 4 mg/m2 | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |